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Danofloxacin is a veterinary fluoroquinolone used to treat respiratory and gastrointestinal diseases of birds, 
pigs and cattle. The literature reviewed shows some analytical methods to quantify this fluoroquinolone, 
but microbiological and biological safety studies are limited. The analytical methods were validated by the 
Official Codes. The LC-DAD method was developed and validated using an RP-18 column, mobile phase 
containing a mixture of 0.3% triethylamine (pH 3.0) and acetonitrile (85:15, v/v). The microbiological 
assay was performed by agar diffusion method (3 x 3) and Staphylococcus epidermidis as a microorganism 
test. Forced degradation studies were performed in both methods. The minimum inhibitory concentration 
(MIC) was performed by test microdilution and toxicity studies were evaluated using in silico study, cell 
proliferation, cell viability test, micronuclei and comet assay. LC and a microbiological assay proved 
linear, accurate, precise, and robust to quantify danofloxacin, but only the LC method showed selectivity 
to quantify the drug in the presence of its degradation products. These results demonstrate that the LC 
method is suitable for stability studies of danofloxacin, but a microbiological assay cannot be used to 
quantify the drug due to the biological activity of the photoproducts. Ex-vivo cytotoxicity and theoretical 
and experimental genotoxicity were also observed. 





4-oxoquinoline-3-carboxylic acid) is a fluoroquinolone 
synthetic analogue of ciprofloxacin and was introduced 
in the world market in 1991 for the treatment of diseases 
related to the respiratory and gastrointestinal tracts of 
birds, pigs and cattle (Mckellar, Gibson, McCormac, 1998; 
Kaur et al., 2012). 
The drug has a broad spectrum of action against 
Gram negative and Gram positive bacteria, as well as 
mycoplasma and against intracellular pathogens such as 
Chlamydia and Brucella (Mckellar, Gibson, McCormac, 
1998; Escudero et al., 2007; Soler, 2014).
The development of fluoroquinolones led to major 
advances in the treatment of infections due to their high 
potency, broad spectrum, bactericidal activity, in addition 
to optimal pharmacokinetic characteristics and their use 
both in medicine and in veterinary medicine (Soler, 2014; 
Souza et al., 2004; Picó, Andreu, 2007; Wolfson, Hooper, 
1985).
The International Conference on Harmonisation 
E. W. F. Cordeiro, R. M. Hilgert, Luiz A. C. Batista, Raul O. Souza, Luís F. S. Oliveira, Michel M. Machado, Marcelo D. Malesuik,  et al.
Braz. J. Pharm. Sci. 2020;56:e18355Page 2 / 12
(ICH) and the International Cooperation on Harmonisation 
of Technical Requirements for Registration of Veterinary 
Medicinal Products (VICH), describe and recommend 
drugs for stability studies with a view to developing 
methods for the quantification, identification and 
structure elucidation of drugs and their respective 
degradation products. Currently, this is one of the 
minimum requirements for the registration of drugs and 
drug products. Moreover, biological safety studies are 
necessary in order to ensure the effectiveness and safety 
of such products (ICH, 2003; VICH, 1998).
The literature review shows some physicochemical 
methods to quantify this fluoroquinolone. Hubicka et al. 
(2014) describes a method of quantification by LC to 
DAN in the presence of photoproducts. Liu et al. (2011) 
published a study using LC-MS for the quantification 
of hydrolysis products, oxidation and photolysis. A 
study by LC-MS to determine the drug in bovine muscle 
and milk is also described (Van Hoof et al., 2005). 
Galarini et al. (2009) report the separation of quinolones 
introduced in animal feed using LC with fluorescence 
and ultraviolet detection. Rodríguez-Cáceres et al. (2009) 
developed an LC method using electrochemical detection 
and a cell with high sensitivity for the simultaneous 
determination of DAN, difloxacin and sarafloxacin. 
However, microbiological studies are limited and there 
are no cytotoxicity and genotoxicity studies for DAN in 
the presence of its degradation products. 
In this sense, these studies aimed to develop 
and validate a stability indicating method by LC and 
microbiological assay for the quantitative determination 
of DAN mesylate in injectable solution, to determine the 
MIC and assess drug genotoxicity and cytotoxicity in 
the presence of its degradation products obtained under 
stressed conditions. The potential toxicity of degradation 
products was also evaluated by different software in order 
to verify if the drug could damage biological cells. These 
results may help to understand the mechanisms of toxic 




The chemical reference substance of DAN (DAN 
CRS) was acquired from Sigma-Aldrich® (St. Louis, MO, 
USA). The injectable solution (Advocin® 2.5%, Pfizer®) 
was acquired from Agroline® Agricultural Products 
(Campo Grande/MS, Brazil). Chemicals used were of 
analytical grade or LC grade. Purified water was prepared 
using Milli-Q Plus® (Millipore, Bedford, USA). The 
formulation excipients were all pharmaceutical grade and 
were purchased from different suppliers: 2-pyrrolidone 
(Merck®), povidone CI5 (Sigma -Aldrich®), magnesium 
oxide (Synth®), phenol (Merck®), monothioglycerol 
(Sigma -Aldrich®), HCl (Nuclear®), NaOH (Nuclear®) 
and purified water (Milli-Q Plus®). The Mueller Hinton 
culture media was acquired from Himedia® (Mumbai, 
India) and the antibiotic number 11 was acquired from 
Merck® (Darmstadt, Germany). 
Apparatus
A Shimadzu Prominence® liquid chromatograph 
(Kyoto, Japan) equipped with a model LC-20AD 
quaternary pump, SIL-20AC HT auto sampler, CTO-
20AC column oven, SPD-M20A photodiode-array 
detector and LC Solution V. 1.24 SP1 manager system 
software was used. Photodegradation studies were carried 
out in a photostability UV chamber (1.0 x 0.17 x 0.17 m) 
with mirrors and equipped with Ultraviolet-C radiation 
lamps (UVC, Light Express®, 254.0 nm). An electronic 
caliper (Mitutoyo®, Tokyo, Japan) was utilized to measure 
the diameters in the zone of growth inhibition (mm). A 
spectrophotometer (Analyser®, São Paulo, Brazil) was 
used in the microorganism standardization. A Nova Ética 
dry heat incubator (São Paulo, Brazil) was used in the 
thermal degradation studies. 
Chromatographic conditions by LC method
The chromatographic separation was performed in 
a Supelco Ascentis® column RP-18 (150 x 4.6 mm I.D., 
5 µm, St. Louis, MO, United States). The mobile phase 
comprised a mixture of 0.3% triethylamine (pH adjusted to 
3.0 with 10% formic acid, v/v) and acetonitrile (85:15, v/v) 
at a flow-rate of 1.0 mL min-1 with isocratic elution. The 
injection volume was 20 µL for both reference substance 
and drug product solutions and the run time was 8 min. 
The temperature was set at 30 °C in the column oven. The 
drug was determined by UV detection at 283.0 nm using 
a diode array detector (DAD).
Agar diffusion bioassay (3 x 3)
The bioassay followed the 3 × 3 parallel line assay 
design with three doses of the standard and three doses 
of the sample in each plate, using eight plates for each 
assay, according to the procedure described in USP 38 
(2015). The base layer agar was composed by 20 mL of 
medium number 11 that was poured into 100 mm × 20 mm 
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Petri dishes. After that layer solidified, 5.0 mL portions 
of the antibiotic medium number 1 were poured onto the 
base layer. In each plate, six stainless steel cylinders of 
the same size (8 mm × 6 mm × 10 mm) were placed on 
the surface of the inoculated medium. Three alternate 
cylinders were filled with 200 µL of the reference solutions 
(S1, S2, and S3), and the other three cylinders were filled 
with the sample solutions (T1, T2, and T3). The plates 
were incubated at 35 ± 2 °C for 18 h. The diameters of 
the growth inhibition were carefully measured with an 
electronic caliper.
The preliminary tests were performed using 
Staphylococcus aureus ATCC 6531p, Staphylococcus 
epidermidis ATCC 12228 and Escherichia coli ATCC 
10536 as microorganism tests. The 24h growth of the 
microorganisms at 35 ± 2 °C was suspended in 0.9% NaCl 
sterile solution and standardized in a spectrophotometer 
(25±2% transmittance, 580 nm). A 2% inoculum solution 
was prepared from this solution in number 11 medium.
The potency of the drug was statistically calculated 
by parallel line model, designed for the 3 × 3 testing 
assay. An analysis of variance (ANOVA) was used for 
the statistical validation of tests, evaluating the regression 
parallelism and linearity of each test (USP 38, 2015; 
Hewitt, 2003; Brazilian Pharmacopeia, 2010).
Validation of the analytical method by LC and 
microbiological assay
The analytical methods were validated according to 
the Guide for Validation and Analytical Quality Control 
(GVCQA) (Brasil, 2011) and other Official Codes (USP 
38, 2015; Hewitt, 2003; Brazilian Pharmacopeia, 2010). 
The parameters available were specificity, linearity, 
precision, accuracy and robustness. The limits of detection 
(LOD) and quantification (LOQ) were determined only 
for the LC method.
Preparation of DAN CRS and Sample solutions for 
the LC method
An accurately weighed amount of DAN CRS 
(5.0 mg) was transferred to a 100 mL volumetric flask and 
dissolved in purified water to obtain a final concentration 
of 50.0 μg mL-1. Successive dilutions were performed in 
the same diluent to obtain a concentration of 10.0 μg mL-1 
in DAN.
To prepare a sample solution, an aliquot of 1 mL of 
the injectable solution (Advocin® 2.5%) was transferred 
to a 100 mL volumetric flask, completed to volume with 
purified water and homogenized, obtaining a solution 
of 250 μg mL-1 in DAN. Successive dilutions were 
performed in the same diluent to obtain a concentration 
of 10.0 μg mL-1 in DAN.
All the solutions were protected from light and 
filtered through a 0.45 µm membrane filter before 
injection. 
Preparation of DAN CRS and Sample solutions for 
the microbiological assay 
DAN CRS was dissolved in purified water to obtain 
a solution of 250.0 μg mL-1. Aliquots of DAN CRS and 
Advocin® were diluted in pH 5.8 phosphate buffer, to 
achieve concentrations of 5.0, 10.0, and 20.0 μg mL-1 
(S1, S2, and S3, respectively for DAN CRS and T1, T2, 
and T3, respectively for Advocin®). All solutions were 
protected from light.
Specificity
Forced degradation studies were performed to 
provide the stability-indicating property and specificity of 
proposed methods. The interference of excipients in both 
methods was evaluated and blank solutions were used 
during the analysis. For the peak purity test for the LC 
method, a DAD was used and the purity factor was also 
evaluated as a support to analyze peak homogeneity. The 
stress conditions were then performed under photolytic, 
acid, basic, oxidative and thermal conditions for the LC 
method and only under photolytic conditions during 48 
hours for the microbiological assay. 
Photolytic conditions
Aliquots of sample solution (250 μg mL-1 in DAN) 
were transferred to a quartz cuvette, irradiated for 1, 2, 4, 
8, 12, 24, and 48 hours in a photodegradation chamber. 
After the time of exposure, dilutions were performed 
in purified water to obtain a final concentration of 10.0 
μg mL-1 in DAN. Control samples were prepared using 
the same procedure described below and also placed 
exposed concurrently into the light chamber, protect 
with aluminium foil, to verify the interference of the 
temperature in the experiments.’’
Thermal conditions
Aliquots of sample solution (250 μg mL-1 in DAN) 
were transferred to eppendorfs and put in a dry heat 
incubator at a controlled temperature of 80 ± 2 °C for 
different time intervals (1, 2, 4, 6, 8 and 24 hours). After the 
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time of exposure, dilutions were performed in purified water 
to obtain a final concentration of 10.0 μg mL-1 in DAN. 
Acid and alkaline conditions
To evaluate DAN stability in acid and alkaline 
conditions, aliquots of the injectable solution were 
diluted in NaOH and HCl solutions (1, 2, and 5 mol L-1) 
to obtain a concentration of 250 μg mL-1 in DAN. These 
solutions were maintained for 1, 2, 4, 6, 8, and 24 hours, 
neutralized and diluted with purified water to obtain a final 
concentration of 10.0 μg mL-1 in DAN.
Oxidative conditions
To evaluate the behaviour of the drug under 
oxidative conditions, aliquots of the injectable solution 
were diluted with 3% or 30% hydrogen peroxide solution. 
The drug was maintained under these conditions for 1, 2, 
4, 6, 12, and 24 hours and diluted with purified water to 
obtain a final concentration of 10.0 μg mL-1 in DAN.
Excipients
An amount of formulation excipients contained in 
2.5% injectable solution of danofloxacin was dissolved in 
purified water, transferred to a 25.0 ml volumetric flask 
and the volume was completed using the same diluent. The 
same aliquots used to prepare the sample solutions were 
withdrawn and the volume diluted with purified water.
Linearity
The linearity of the LC method was performed using 
three calibration curves with six concentrations (2.5; 
5.0; 7.5; 10.0; 15.0; and 20.0 μg mL-1) of DAN CRS in 
purified water. For each concentration the solutions were 
prepared and injected in triplicate. The regression line was 
calculated using the method of least squares and the curves 
were validated through analysis of variance.
The linearity of the microbiological assay was 
carried out using three levels of CRS DAN concentrations 
(5.0; 10.0; and 20.0 μg mL-1) in phosphate buffer pH 5.8. 
Standard curves were obtained on different days and 
measures of inhibition zones were plotted on graphs of 
inhibition zones versus logarithm of the concentration.
Precision
The precision in both methods was evaluated using 
the parameters of repeatability and intermediate precision, 
performed on different days by different analysts. 
The results were expressed as RSD of the analytical 
measurements.
Accuracy
The accuracy of the methods was calculated as 
recovery percentage by adding known amounts of the 
DAN CRS solutions to sample solutions. 
Robustness
A Plackett-Burman experimental design of 12 
experimental runs was performed to verify the robustness 
of the LC method. The factors investigated were: pH 
of aqueous phase (3.0 ± 0.2), percentage of acetonitrile 
(15 ± 2%), flow (1.00 ± 0.05 ml min-1), wavelength 
of detection (283 ± 3 nm) and column manufacturer 
(Supelco® and Shimadzu®). To evaluate the robustness of 
the microbiological assay, the factors assessed were the 
inoculum concentrations (1.7% and 2.3%) and the use of 
different ovens for incubation of the plates.
LOD and LOQ
LOD and LOQ of the drug using the LC method 
were obtained based on the signal-to-noise approach 
described by Ermer and Miller (2005). The background 
noise was obtained after injection of the blank solution, 
observed over a distance equal to 20 times the width at 
half-height of the DAN peak (10.0 μg mL-1). LOD and 
LOQ values were experimentally determined with six 
replicates using the signal-to-noise ratio of 3:1 and 10:1, 
respectively.
Minimum inhibitory concentration (MIC)
Microorganism standardization
The assays to determine the MIC were performed 
according to protocol M100-S25 of the Clinical and 
Laboratory Standards Institute (CLSI, 2015). The 
microbial suspension was standardized using optical 
density at 530.0 nm in the range of 0.09 to 0.13A. Assays 
were performed using these solutions diluted in Mueller 
Hinton broth at a ratio of 1:10 (v/v).
Microdilution assay
In order to prepare a sample solution, aliquots of 
injectable solution (Advocin® 2.5%) were diluted using 
purified water obtaining a concentration of 10 µg mL-1 in 
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DAN. Shortly after, successive solutions were performed 
in Mueller Hinton culture medium to obtain final 
concentrations ranging from 0.03 to 12.8 µg mL-1.
The tests were performed in sterile plates containing 
96 wells in which aliquots of 100.0 µL of various 
concentrations of the antimicrobial agent were added. 
Subsequently, aliquots of 5.0 µL of the standardized 
inoculum were added to each well. An antibiotic-
free control (growth control) and a free control of 
microorganisms (sterility control) were included in the 
tests and the plates were incubated at 35 ± 2 °C, for 
18-24 h. The MIC determination was carried out by visual 
comparison to the growth control, and all assays were 
performed in triplicate.
After the MIC was defined, further tests were 
conducted to evaluate the drug activity which showed 
changes when it was exposed to stress conditions by UV-C 
radiation for 12, 24, and 48 hours, prepared as described 
in the LC method.
Biological safety studies
The white blood cell cultures were prepared using a 
blood sample collected from a volunteer donor, according 
to procedures approved by the Research Ethics Committee 
of the Federal University of Santa Maria (Letter of 
approval No. 27045614.0.0000.5323). Venous blood 
was immediately diluted in RPMI 1640 supplemented 
with 10% fetal bovine serum, 5% phytohemagglutinin, 
sodium bicarbonate 2 g L-1, and 1% streptomycin/
penicillin at the proportion of 1:1 (v/v). The cells were 
placed in an incubator at 37 °C and 5% CO2, for 72 hours 
(Montagner et al., 2010). Four groups were used for the 
tests and the negative control received PBS 7.4 and the 
positive control 100 mM hydrogen peroxide.
The concentrations tested ranged between 125 and 
0.97 µg mL-1 of the drug in PBS 7.4 buffer. The drug was 
also submitted to forced degradation under photolytic 
conditions (48 hours) to evaluate the toxic potential in 
the presence of degradation products. All assays were 
performed in triplicate.
The study of cellular viability was evaluated by 
the loss of membrane integrity using the trypan blue test. 
Cells exposed to the dye were analyzed microscopically 
in a Neubauer chamber and the results were expressed as 
percentage of the control value (Burow et al., 1998).
Cell proliferation analyses were also performed in 
a Neubauer chamber to differentiate between living and 
dead cells, observing the blue colour of the dead cells using 
Turk’s solution as a dye (3% acetic acid and 1% gentian 
violet in water) (Tice et al., 2000).
The comet assay was performed according to 
Montagner et al. (2010) and Tice et al. (2000). One 
hundred cells per slide were counted in triplicate for each 
group. Cells were classified according to the length of their 
tail, and the levels of damage were from 0 (no damage) to 
4 (maximum damage).
The micronucleus test was carried out according to 
the technique described by Schmid (1975), which allows 
the identification of increased frequency of micronuclei in 
cells exposed to genotoxic agents, which express damage 
in their chromosomes.
All analyses were performed using toxicity specific 
statistical software. Data were evaluated by ANOVA 
followed by post-hoc Bonferroni. Results were considered 
significant to p < 0.05.
LC-ESI-MS instrumentation and conditions
An LC-ESI-MS method was performed using a 
Shimadzu® instrument equipped with an MS detector. 
The separation was performed using a Supelco Ascentis® 
column (150 x 4.6 mm, 5 μm) at 30 ºC with a mobile 
phase consisting of the mixture of 0.1% formic acid and 
acetonitrile (85:15, v/v) in isocratic gradient at a flow- rate 
of 0.5 mL min-1 with an injection sample volume of 2.0 μL. 
Studies were performed in samples obtained 
after exposition to photolytic conditions using UVC 
radiation, for 24 hours. Mass spectra were acquired 
with an electrospray ionization interface in positive 
ionization mode. The capillary voltage was 2.5 kV; source 
temperature 110 ºC; desolvation temperature 250 ºC; 
nitrogen desolvation flow 900 L h-1; nitrogen cone flow 
90 L h-1. The full scan mass spectrum was acquired over a 
range of m/z 50 – 900.
In silico toxicology
Chemical structures of degradation products 
identified by LC-ESI-MS and confirmed in the studies 
of Hubicka et al. (2014) were submitted to evaluation of 
a theoretical risk of causing toxic effects using three in 
silico toxicity programs, such as Osiris Property Explorer® 
(2017), ADME-Tox ACD/Labs (2017), and pKCSM free 
web software (2017). Osiris Property Explorer was used 
to determine the potential mutagenic, tumorigenic, irritant, 
and toxicant reproductive system effects.
ADME-Tox web server software, ACD/Labs team®, 
was used to study the genotoxic and mutagenic effects, 
using data of a bacterial reverse mutation test (AMES Test) 
Salmonella typhimurium TA97a, TA98, TA100, TA102, 
TA104, TA1535, TA1537 and TA1538. Other software 
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used to predict the toxicity of degradation products are 
PKCSM which is a free web software used to determine 
the potential toxic effects, such as hERG I and II inhibitor, 
hepatotoxicity, AMES toxicity, and skin sensitization 
(Pires, Blundell, Ascher, 2015).
RESULTS AND DISCUSSION
Development and validation of the LC method
The chromatographic conditions were chosen 
after testing different mobile phases with distinct ratios 
of organic solvent (acetonitrile or methanol) and water, 
with and without triethylamine at different pH values. 
Ammonium acetate buffers were also tested. The use of 
acetonitrile as an organic component and the addition of 
triethylamine (0.3%, v/v) in the aqueous phase (pH 3.0) 
improved peak symmetry. 
 T h e  m o b i l e  p h a s e  c o n s i s t i n g  o f  0 . 3 % 
triethylamine pH 3.0 (adjusted with 10% formic acid 
solution, v/v) and acetonitrile (85:15, v/v) showed the 
best system suitability values, with suitable resolution 
between the drug and the degradation products and results 
in terms of peak parameters (peak shape, theoretical 
plates, symmetry and retention factor) according to the 
range recommended (USP 38, 2015). Moreover, the 
retention time observed (rt = 6.0 min) allows for a rapid 
determination of the drug.
Figure 1 showed that formulation excipients (1A) did 
not interfere in the quantification of the drug (1B – DAN 
CRS). Moreover, the method demonstrated selectivity to 
quantify the drug in the presence of degradation products, 
obtained from stress conditions. 
The result showed that under oxidative conditions 
(Figure 1C) it was possible to verify the formation of two 
degradation products, detected at 3.63 and 6.75 minutes. 
Under these conditions the drug degraded 19.3% and 
35.1% in 12 and 24 hours, respectively. 
Under photodegradation conditions (Figure 1D), 
three degradation products were formed (3.23, 4.14, 
and 11.47 min.). The drug degraded 15.25% in 24 hours 
and 25.5% in 48 hours. These results showed the drug 
instability under photolytic and oxidative conditions. 
Control samples demonstrated that the heat generated 
inside the light chamber did not interfere in drug 
degradation. 
The concentration of danofloxacin decreased 
significantly under oxidative and photolytic conditions. 
However, there were no changes in drug concentration 
when the drug was exposed to alkaline and acid hydrolysis 
(1.0; 2.0 and 5.0 mol L-1) and temperature of 80 °C for 
24 h. 
The chromatographic peak purity tool, applied to 
DAN peaks, demonstrated that they were pure in all cases, 
confirming the absence of another substance coeluting 
at the same retention time. Moreover the method proves 
to be a stability indication and there is a clear ability to 
assess the drug unequivocally in the presence of potential 
interference.
To assess linearity, three standard curves for DAN 
CRS were constructed by plotting concentration (µg 
mL-1) versus area (mAU). The results showed adequate 
linearity in the range of 2.5 and 20.0 µg mL-1. The linear 
equation, obtained by linear regression by minimum 
squares method, was y = 180679x - 137386 and the 
correlation coefficient (r) was 0.9994, indicating a linear 
FIGURE 1 - Chromatograms obtained from DAN in injectable solution by LC: (A) placebo solution of excipients; (B) drug product 
DAN; (C) oxidative degradation (30% H2O2, for 24 hours); (D) photodegradation (UV-C radiation, for 48 hours). * hydrogen 
peroxide preservative.
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relationship between the concentrations and the areas 
obtained. The ANOVA results showed linear regression, 
with no deviation from linearity (α = 0.05), confirming the 
linearity of the analytical method.
The precision of the analytical method was 
demonstrated by repeatability (intraday) and intermediate 
precision (interday). The experimental values obtained for 
quantitative determination of the drug in three days were 
101.23 ± 0.88%, 100.95 ± 1.4% and 104.33 ± 1.8%. The 
low variability of the results indicated method precision.
Results showed method accuracy using the standard 
addition technique. The average recovery percentages 
were in the range of 99.45 ± 0.62%, 99.93 ±0.76% and 
100.21 ± 0.82%, demonstrating the accuracy of the 
method.
The method can be considered robust because none 
of the studied factors showed a significant effect (α = 
0.05) on the quantification of DAN (Table I). Besides, 
the variation of robustness results (RSD = 0.79%) is in 
accordance with the results of the precision assay.
Microbiological assay
All microorganisms used in the microbiological 
assay showed sensitivity to the drug, but significant 
differences could be seen between the growth inhibition 
zones. The assay using Staphylococcus epidermidis at 
5.0, 10.0 and 20.0 µg mL-1 showed well defined growth 
inhibition zones, allowing an accurate and precise 
determination.
Curves of DAN CRS, constructed by plotting log 
concentration versus growth inhibition zone, showed good 
linearity in the studied concentration range, with a mean 
correlation coefficient (r = 0.9998) and linear equation, 
obtained by linear regression by the minimum squares 
method, was y = 7.136x + 14.71.
Assay precision was determined by repeatability 
(intraday) and intermediate precision (interday). 
Repeatability was assessed by determining the power of 
the samples in three tests performed simultaneously at 
the same concentrations and under the same experimental 
conditions. The results showed RSD values lower 
than 5.0%, indicating the intra-assay precision. The 
antimicrobial activity comprises a range from 102.9% to 
106.7% and RSD of 1.3%. 
The robustness of the analytical method was 
evaluated using different concentrations of inoculum (± 
0.3%) and different air ovens. The modification in the 
inoculum concentration showed results in the range of 
103.5% to 104.76% and the alteration of the air oven 
showed a result with a 103.18% potency. These values 
obtained are within the range found in the precision 
studies, confirming the robustness of the analytical 
method.
TABLE I - Plackett-Burmann experimental design to evaluate the robustness of the analytical method
Exp pH DUMMY DUMMY λ (nm) DUMMY DUMMY DUMMY %ACN COLUMN FLOW DUMMY %DAN
1 + + - + + + - - - + - 100.20
2 - + + - + + + - - - + 99.36
3 + - + + - + + + - - - 100.72
4 - + - + + - + + + - - 101.56
5 - - + - + + - + + + - 100.68
6 - - - + - + + - + + + 99.55
7 + - - - + - + + - + + 100.02
8 + + - - - + - + + - + 99.72
9 + + + - - - + - + + - 101.12
10 - + + + - - - + - + + 100.21
11 + - + + + - - - + - + 99.67
12 - - - - - - - - - - - 101.73
(+) 100.24 100.36 100.29 100.32 100.25 100.04 100.39 100.49 100.38 100.30 99.76
(-) 100.52 100.40 100.46 100.44 100.51 100.72 100.37 100.27 100.37 100.46 101.00
Effect -0.27 -0.03 -0.17 -0.12 -0.26 -0.68 0.02 0.21 0.01 -0.16 -1.25
Error 0.646
tcalc 0.42 0.26 -0.19 -0.33 0.02 -0.25
tcrit (p < 5%) 2.57
The LOD and LOQ for the proposed method were 0.13 and 0.52 µg mL-1, respectively, evidencing the sensitivity of the analytical method.
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The specificity of the microbiological assay was 
performed to verify the interference of formulation 
excipients and degradation photoproducts formed under 
stress conditions. The results showed that the placebo 
solution did not produce growth inhibition zones, 
demonstrating that it did not interfere. Furthermore, 
the diameters of the growth inhibition zones were not 
increased when excipients were added to the DAN CRS. 
The same conditions employed in the forced 
degradation studies using the LC method were applied 
in microbiological assays. The results showed that the 
drug potency was not decreased using the degraded 
samples under photolytic conditions, suggesting that the 
photodegradation products have biological activity, which 
limits the drug quantification in stability studies using the 
microbiological assay. However, the LC method proved 
suitable to quantify the DAN drug and can be used as 
routine analysis and stability studies. The oxidative stress 
conditions could not be assessed due to the bactericidal 
activity of the 30% H2O2 solution.
Microdilution assay
The in vitro susceptibility of the three strains 
examined is shown in Table II. The samples subjected 
to stress conditions showed that the residual of drug 
levels is reduced over time as discussed above. However, 
when comparing the assay in vitro samples submitted to 
photodegradation with the undegraded samples, some 
changes are identified in the MIC.
After 12 hours of degradation, the drug content is 
reduced to 93%, and the MIC obtained for S. aureus remains 
the same. However, after 24 and 48 hours, the concentration 
required to inhibit growth was twice the MIC for the 
drug. The opposite was found for S. epidermidis, where 
danofloxacin in the presence of degradation products (DAN 
DP) at 24 and 48 hours, had higher activity when compared 
to DAN and DAN DP at 12 hours. Regarding the DAN MIC 
for E. coli, the result shows that drug activity is reduced 
with degradation. However, the reduction of the MIC is not 
directly proportional to the drug content.
Biological safety testing
The evaluation of toxicity using parameters and 
leukocyte cultures has proved to be a significant in vitro 
research tool for evaluating damage to membranes, cellular 
activity and proliferation index. The results of the effect of 
DAN and DAN DP at 48 hours in leukocyte proliferation are 
shown in Figure 2A and it is possible to observe a significant 
difference between the groups tested. The amount of cells 
declined significantly at higher concentrations of DAN DP 
(125.0 and 62.5 µg mL-1), as also described for positive 
control. However, no significant changes were observed 
in the number of leucocytes at other concentrations (31.25 
to 0.97 µg mL-1) in the same group and these results were 
statistically similar to the negative control (p=0.05). 
The percentage of viable cells (Figure 2B) exposed 
to DAN drug was not significantly decreased compared 
with the negative control, demonstrating that the drug 
proved non-toxic at the concentrations applied. However, 
DAN DP showed similar behaviour to the positive control 
group, indicating that the degradation products may be 
responsible for damage to the membrane by promoting cell 
death. Similar results were obtained for the gemifloxacin 
degradation product, where significant dose-dependent 
cytotoxic and genotoxic activity was verified using rat 
fibroblast (3T3) (Paim et al, 2013).
The DNA Damage Index (DDI) (Figure 2C) was 
evaluated by comet assay. The trials indicated that none 
of the concentrations of DAN drug (range of 125.0 to 
0.97 µg mL-1) and DAN DP at 31.25 to 0.97 µg mL-1 
demonstrated genotoxic potential, because the results 
were statistically similar to negative control (p=0.05). 
However, DAN PD showed a genotoxic potential at high 
concentrations (125.0 and 62.5 µg mL-1), because the 
damage index results were statistically different from the 
negative control. 
The results of micronuclei formation in the cell 
cultures can be observed in Figure 2D. The trials indicated 
that high concentrations of DAN drug and DAN DP (125.0 
and 62.5 µg mL-1) may be responsible for the formation of 
micronuclei in the cells used in these studies. 







MIC DAN (µg mL-1) 0.10 0.10 0.06
MIC DAN DP 12h (µg mL-1) 0.10 0.10 0.12
MIC DAN DP 24h (µg mL-1) 0.20 0.05 0.12
MIC DAN DP 48h (µg mL-1) 0.20 0.05 0.12
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According to many studies the toxic potential of 
the fluoroquinolones is directly related to the chemical 
structure of the molecule and varies with substituent groups. 
Different substituents in the basic structure of quinolones are 
intrinsically linked to the molecule toxicity. The genotoxic 
and cytotoxic potential of these drugs is mainly attributed 
to the presence of the cyclopropyl group, but there are also 
reports of toxicity of compounds which have substituent 
groups such as tert-butyl, 2.5 dihydrophenyl and ethyl group 
in position 1 (Lipsky, Barker, 1999).
Substituents at position 7 also influence the toxicity 
and toxic effects on the central nervous system (CNS), 
genotoxic and dermatological reactions. The effects on the 
CNS are due to interactions with GABAergic receptors, 
blocking the GABA union. Dermatological effects are 
due to the production of reactive species from interaction 
with ultraviolet light, causing reactions at the cellular 
level that manifest themselves in the form of rashes, hives, 
itching of the skin and other local irritations. Similarly 
genotoxic activity is attributed to some substituents in 
the same position and is more pronounced in molecules 
with a pyrrolidine ring compared to molecules with a 
substituent piperazine ring (Domagala, 1994; Briskier, 
Chantot, 1995).
Genotoxic potential is also related to a substituent 
at position 8 of the quinolones, for which fluoride, C - Cl, 
N, CH, C-CF3, and OR are mainly responsible. In the 
same position photosensitivity reactions are attributed 
to fluoride and methoxy substituents, as described for 
lomefloxacin and sparfloxacin (Briskier, Chantot, 1995).
Identification of the photodegradation products 
by LC-ESI-MS
The results using LC-ESI-MS showed that the 
main degradation products under photolytic conditions 
have the following molecular mass: 358.1; 251.07 and 
291.10 g mol-1 and were named DP1, DP2 and DP3. 
These degradation products coincide with the degradation 
products DP1, DP5 and DP12 cited in the literature by 
Hubicka et al. (2014).
In silico toxicology studies
The theoretical risks of toxicity, such as tumorigenic, 
mutagenic, irritant effects, and damage to the reproductive 
system by DAN DP1, DAN DP2, and DAN DP3, indicated 
in this work, were first studied using Osiris software. Osiris 
is based on the analysis of a precomputed set of structural 
fragments that gave off toxicity alerts when they were 
encountered in the molecule. This program uses the drug 
database marketed and also Fluka chemical compounds 
(no therapeutic drugs) to assess the frequency of each 
fragment present in the compounds studied. All results 
for chemical structure and standard H2O2 using Osiris 
software are shown in Table III.
FIGURE 2 - Biological safety studies in cultures of human leukocytes: (A) Effects of DAN and DAN DP on cell proliferation; 
(B) Leukocyte evaluation of cell viability as measured by Trypan blue dye after exposure to different concentrations of DAN and 
DAN DP; (C) Comet Assay: Damage Index to DNA cells exposed to different concentrations of DAN and DAN DP; (D) Effects 
of DAN and DAN DP in the production of micronuclei in cell cultures.
E. W. F. Cordeiro, R. M. Hilgert, Luiz A. C. Batista, Raul O. Souza, Luís F. S. Oliveira, Michel M. Machado, Marcelo D. Malesuik,  et al.
Braz. J. Pharm. Sci. 2020;56:e18355Page 10 / 12
The evaluation of these degradation products 
showed a prediction of a low risk of causing theoretical 
toxic effects, tumorigenic and mutagenic effects, and 
damage to the reproductive system compared with the high 
risk for H2O2. The software also suggested that there is a 
low risk of an irritant effect, and the same was observed 
for standard H2O2.
The ACD/Labs team web server is software used 
to predict the fragments that could lead to possible DP1, 
DP2, and DP3 toxic effects. This software suggests 
the occurrence of genotoxic properties and a toxicity 
mechanism. According to software, toxicity should be 
observed in two molecular regions. In the first molecular 
region, the presence of the aromatic amine moiety attached 
to the quinolone nucleus of DP2 and DP3 may undergo 
biotransformation and generate hydroxylamine which 
may be genotoxic to biological cells. The second region, 
the quinone moiety, was identified in three compounds 
evaluated. This chemical moiety is an electrophilic agent 
which may form adducts with guanine nucleobases and 
induce DNA damage after metabolic activation.
Once the results of the theoretical risk of toxicity in 
the AMES test Salmonella typhymirium was evaluated, a 
probability of 0.42 and 0.76 of DP2 and DP3, respectively 
to cause a mutagenic effect was determined. In comparison 
with molecules present in a program database, which 
cause effects against strains TA97a, TA98, TA100, 
TA102, TA104, TA1535, TA1537, and TA1538, there 
was no toxicity in most of the tested bacterial strains. 
In this scenario, DP2 showed a mutagenic effect on the 
TA98 strain when it was compared to compound bis-
2-hydroxy-4-amino-benzene (CAS 2373-98-0), with a 
similarity index of 0.21. DP3 showed the same predicted 
effect on strain TA100 compared to the chemical structure 
of 3-amino-5-methylphenol (CAS: 95-84-1), similarity 
index of 0.18.
pkCSM is a software based on graph-based 
signatures which are used to develop predictive models 
of central ADMET properties. This computational tool 
employs the calculated nodes distance and also the 
physicochemical properties of toxic compounds by 
machine learning-based predictors to predict the toxicity 
of chemical agents (Pires, Blundell, Ascher, 2015). With 
this software the prediction of DP1 and DP3 showed a 
positive effect on AMES test toxicity and hepatotoxicity. 
DP2 did not show a potential risk of a hepatotoxic effect. 
These compounds were not considered a hERG I and II 
inhibitor, that caused skin sensitization.
In toxicity predictions, two computer programs 
suggest the potential risks that DP2 and DP3 may have 
a genotoxic effect considering the AMES test database. 
These results are in agreement as observed with ex-vivo 
Comet assay studies performed here. All results suggest 
that DAN should be used carefully in the presence of 
degradation products.
CONCLUSIONS
The method developed and validated by LC proved 
selective for the quantitative determination of DAN and 
its degradation products obtained under stress conditions. 
The microbiological assay proved to be precise, accurate, 
robust and linear, but not selective to quantify the drug 
in the presence of degradation photoproducts. In the 
in vitro assay to evaluate the MIC, DAN PD showed 
reduced activity against S. aureus and E. coli, but it 
showed increased activity against S. epidermidis, which 
suggests that the degradation products have biological 
activity. Biological safety studies using a leukocyte culture 
demonstrated that the degradation products showed dose 
dependent cytotoxicity and genotoxicity.
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